MacroGenics

MGNX NASDAQ
14.69
-0.45
-2.97%
After Hours: 14.69 0 0.00% 17:04 07/19 EDT
Open
15.17
Prev Close
15.14
High
15.18
Low
14.66
Volume
335.91K
Avg Vol (3M)
801.74K
52 Week High
32.32
52 Week Low
9.87
% Turnover
0.69%
Market Cap
716.95M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers MacroGenics MGNX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
MORE >

Recently

Name
Price
%Change